DK1240337T3 - Fremgangsmåder og præparater til forlængelse af elimeneringshalveringstider af bioaktive forbindelser - Google Patents

Fremgangsmåder og præparater til forlængelse af elimeneringshalveringstider af bioaktive forbindelser

Info

Publication number
DK1240337T3
DK1240337T3 DK00988373T DK00988373T DK1240337T3 DK 1240337 T3 DK1240337 T3 DK 1240337T3 DK 00988373 T DK00988373 T DK 00988373T DK 00988373 T DK00988373 T DK 00988373T DK 1240337 T3 DK1240337 T3 DK 1240337T3
Authority
DK
Denmark
Prior art keywords
hybrid
elimination half
molecule
molecules
domain
Prior art date
Application number
DK00988373T
Other languages
English (en)
Inventor
Mark S Dennis
Henry B Lowman
Warren L Delano
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1240337T3 publication Critical patent/DK1240337T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Processing Of Solid Wastes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK00988373T 1999-12-24 2000-12-22 Fremgangsmåder og præparater til forlængelse af elimeneringshalveringstider af bioaktive forbindelser DK1240337T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17304899P 1999-12-24 1999-12-24
PCT/US2000/035325 WO2001045746A2 (en) 1999-12-24 2000-12-22 Methods and compositions for prolonging elimination half-times of bioactive compounds

Publications (1)

Publication Number Publication Date
DK1240337T3 true DK1240337T3 (da) 2007-01-02

Family

ID=22630310

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00988373T DK1240337T3 (da) 1999-12-24 2000-12-22 Fremgangsmåder og præparater til forlængelse af elimeneringshalveringstider af bioaktive forbindelser

Country Status (12)

Country Link
US (3) US7608681B2 (da)
EP (2) EP2180054A1 (da)
JP (3) JP2003518075A (da)
AT (2) ATE337403T1 (da)
AU (3) AU784285B2 (da)
CA (2) CA2390691C (da)
CY (1) CY1106236T1 (da)
DE (2) DE60041564D1 (da)
DK (1) DK1240337T3 (da)
ES (1) ES2270893T3 (da)
PT (1) PT1240337E (da)
WO (1) WO2001045746A2 (da)

Families Citing this family (262)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69926009D1 (de) 1998-10-13 2005-08-04 Univ Georgia Res Found Stabilisierte bioaktive peptide und methoden zu ihrer identifikation, synthese und verwendung
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
DK1240337T3 (da) 1999-12-24 2007-01-02 Genentech Inc Fremgangsmåder og præparater til forlængelse af elimeneringshalveringstider af bioaktive forbindelser
DE10012120A1 (de) * 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
DE50112802D1 (de) * 2000-11-08 2007-09-13 Fresenius Medical Care Affina Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
AU2002335930B2 (en) 2001-03-09 2005-07-28 Morphosys Ag Serum albumin binding moieties
US20030157561A1 (en) * 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US6916904B2 (en) 2002-04-24 2005-07-12 Zolaris Biosciences, Llc Inhibition of immune complex formation
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
JP2006507477A (ja) * 2002-06-14 2006-03-02 ダイアックス、コープ タンパク質分析
DK1517921T3 (da) * 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
EP2284192A3 (en) * 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
US7329725B1 (en) 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
PL1718677T3 (pl) 2003-12-19 2012-09-28 Genentech Inc Jednowartościowe fragmenty przeciwciała stosowane jako środki lecznicze
US8754031B2 (en) 2004-03-08 2014-06-17 Oncolix, Inc. Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
WO2005086947A2 (en) * 2004-03-10 2005-09-22 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subjetc
AU2011253771B2 (en) * 2004-03-10 2013-10-31 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subject
JP5634008B2 (ja) * 2004-04-06 2014-12-03 アフィボディ・アーベー 新規の使用および方法
CN102973947A (zh) 2004-06-01 2013-03-20 健泰科生物技术公司 抗体-药物偶联物和方法
JP2008500830A (ja) 2004-06-01 2008-01-17 ドマンティス リミテッド 増加した血清半減期を有する二重特異性融合抗体
CN101035808B (zh) 2004-08-05 2012-10-31 健泰科生物技术公司 人源化抗c-met拮抗剂
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
AU2005286607B2 (en) 2004-09-23 2011-01-27 Genentech, Inc. Cysteine engineered antibodies and conjugates
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
JP4993645B2 (ja) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド 抗体薬剤結合体および方法
US20090191217A1 (en) * 2004-12-02 2009-07-30 De Wildt Ruud M Anti-IL-1R1 Single Domain Antibodies And Therapeutic Uses
BRPI0518761A2 (pt) 2004-12-02 2008-12-09 Domantis Ltd fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente
KR20070099584A (ko) * 2004-12-02 2007-10-09 도만티스 리미티드 도메인 항체와 컨주게이션되어 혈청 반감기가 증가된ｐｌａｄ 도메인 펩티드
RU2464276C2 (ru) 2005-05-18 2012-10-20 Аблинкс Н.В. Улучшенные нанотела против фактора некроза опухоли-альфа
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
WO2007094842A2 (en) 2005-12-02 2007-08-23 Genentech, Inc. Binding polypeptides and uses thereof
EP1940436B1 (en) * 2005-09-06 2013-12-04 Trinity Therapeutics, Inc. Methods for treating immune mediated neurological diseases
US20100015146A1 (en) * 2005-10-14 2010-01-21 Novo Nordisk A/S Treating diabetes using inhibitors of il-1
US7704953B2 (en) * 2006-02-17 2010-04-27 Mdrna, Inc. Phage displayed cell binding peptides
WO2007104789A2 (en) 2006-03-15 2007-09-20 Novo Nordisk A/S Amylin derivatives
SG172656A1 (en) 2006-05-30 2011-07-28 Genentech Inc Antibodies and immunoconjugates and uses therefor
ATE536369T1 (de) * 2006-10-11 2011-12-15 Ablynx Nv Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung
KR101541550B1 (ko) 2006-10-27 2015-08-04 제넨테크, 인크. 항체 및 면역접합체 및 이들의 용도
WO2008071685A1 (en) * 2006-12-13 2008-06-19 Ablynx N.V. Polypeptides specific for complexes involved in receptor-mediated signaling, such as the il-6/il-6 receptor complex
AU2007336243B2 (en) 2006-12-19 2012-07-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
EP3095455A1 (en) 2006-12-19 2016-11-23 Genentech, Inc. Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
US20100062004A1 (en) 2006-12-19 2010-03-11 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
PE20081760A1 (es) 2007-02-09 2009-01-01 Genentech Inc Anticuerpos anti-robo4 y sus usos
UA103004C2 (ru) 2007-07-16 2013-09-10 Дженентек, Інк. Гуманизированное антитело против cd79b и иммуноконъюгаты и способы применения
RS53595B1 (en) 2007-07-16 2015-02-27 Genentech, Inc. ANTI-CD79B ANTIBODIES AND IMMUNOCONCULATES AND METHODS OF USE
WO2009016043A2 (en) 2007-07-31 2009-02-05 Affibody Ab New albumin binding compositions, methods and uses
EP2036923A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
CN104004088B (zh) 2007-09-26 2017-11-07 Ucb医药有限公司 双特异性抗体融合物
KR100920729B1 (ko) * 2007-10-01 2009-10-07 한국생명공학연구원 펩타이드 혼성체를 사용한 배향성이 조절된 항체단분자막의 제조방법
JP2011504740A (ja) 2007-11-27 2011-02-17 アブリンクス エン．ヴェー． ヘテロ二量体サイトカイン及び／又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド
MY157403A (en) 2008-01-31 2016-06-15 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
CA2724208C (en) 2008-05-16 2018-02-06 Ablynx Nv Amino acid sequences directed against cxcr4 and other gpcrs and compounds comprising the same
CA2726652A1 (en) 2008-06-05 2009-12-10 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
CA2729185A1 (en) 2008-06-30 2010-01-21 Esbatech, An Alcon Biomedical Research Unit Llc Methods and compositions for modifying immunobinders
CN102088958A (zh) 2008-07-10 2011-06-08 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 用于大分子的增强的递送的方法和组合物
SG10201500597YA (en) * 2008-07-18 2015-04-29 Trinity Therapeutics Inc Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome
CN102164965B (zh) 2008-09-26 2016-03-30 Ucb医药有限公司 生物产品
JP5703226B2 (ja) 2008-10-21 2015-04-15 ノヴォ ノルディスク アー／エス アミリン誘導体
US9393304B2 (en) 2008-10-29 2016-07-19 Ablynx N.V. Formulations of single domain antigen binding molecules
RU2553214C2 (ru) 2008-10-29 2015-06-10 Аблинкс Н.В. Способы очистки однодоменных антигенсвязывающих молекул
WO2010054699A1 (en) * 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
AU2009316409A1 (en) 2008-11-22 2010-05-27 Genentech, Inc. Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer
CA2747644C (en) 2008-12-19 2023-01-24 Ablynx N.V. Method for generation of immunoglobulin sequences
AU2010218261B2 (en) 2009-02-26 2015-08-20 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
US8648046B2 (en) * 2009-02-26 2014-02-11 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
TWI507205B (zh) 2009-03-25 2015-11-11 Genentech Inc 抗ｆｇｆｒ３抗體及使用方法
AU2010236787A1 (en) 2009-04-01 2011-11-10 Genentech, Inc. Anti-FcRH5 antibodies and immunoconjugates and methods of use
RU2539798C2 (ru) 2009-04-10 2015-01-27 Аблинкс Нв Улучшенные аминокислотные последовательности против il-6r и содержащие их полипептиды для лечения связанных с il-6r заболеваний и нарушений
DK2438087T3 (da) 2009-06-05 2017-08-28 Ablynx Nv Trivalente nanobodykonstruktioner mod human respiratorisk syncytialvirus (hrsv) til forebyggelse og/eller behandling af luftvejsinfektioner
BR112012003346A2 (pt) 2009-08-15 2016-11-16 Genentech Inc metodo de tratamento de um paciente diagnostico com cancer de mama metastico previamente tratado kit para tratamento de cancer de mama metastatico previamente tratado em um paciente humano metodo para instruir um paciente humano com cancer metodo promocional e metodo comercial
CA2809819A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
BR112012009412A2 (pt) 2009-10-22 2016-11-29 Genentech Inc 'anticorpo anti-hepsina isolado, molécula de ácido nucleico, célula hospedeira, método para fabricar um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo e método para fabricar um anticorpo anti-serina protease'
NZ598901A (en) 2009-11-05 2014-08-29 Genentech Inc Methods and composition for secretion of heterologous polypeptides
JP5876416B2 (ja) 2009-11-13 2016-03-02 グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． フォンウィルブランド因子（ｖＷＦ）含有調製品並びにこれに関連する方法、キット及び使用
US9644022B2 (en) 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
US10584181B2 (en) 2009-12-04 2020-03-10 Genentech, Inc. Methods of making and using multispecific antibody panels and antibody analog panels
US20120269830A1 (en) 2009-12-07 2012-10-25 Lawrence Horowitz Conjugates with improved pharmacokinetic properties
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
BR112012020700A8 (pt) 2010-02-23 2018-01-02 Hoffmann La Roche método de tratamento de pacientes diagnosticadas com câncer do ovário, kit de tratamento de câncer do ovário, método de instrução a uma paciente humana com câncer do ovário, método promocional e comercial
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
ES2430567T3 (es) 2010-04-15 2013-11-21 Spirogen Sàrl Pirrolobenzodiacepinas y conjugados de las mismas
EP3546483A1 (en) 2010-05-20 2019-10-02 Ablynx N.V. Biological materials related to her3
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
KR20130098165A (ko) 2010-06-03 2013-09-04 제넨테크, 인크. 항체 및 면역접합체의 이뮤노-ｐｅｔ 영상화 및 그의 용도
SG185428A1 (en) 2010-06-08 2012-12-28 Genentech Inc Cysteine engineered antibodies and conjugates
CN103003296A (zh) 2010-07-09 2013-03-27 阿菲博迪公司 多肽
EP2621538B1 (en) 2010-09-28 2015-12-16 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
CN103328512B (zh) 2010-11-08 2017-04-05 诺瓦提斯公司 Cxcr2结合多肽
ES2544608T3 (es) 2010-11-17 2015-09-02 Genentech, Inc. Conjugados de anticuerpo y de alaninil-maitansinol
PL2643349T3 (pl) 2010-11-26 2020-03-31 Molecular Partners Ag Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy
EP2673297A2 (en) 2011-02-11 2013-12-18 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
EP2691418A1 (en) 2011-03-28 2014-02-05 Ablynx N.V. Bispecific anti-cxcr7 immunoglobulin single variable domains
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
RU2638806C2 (ru) 2011-05-12 2017-12-15 Дженентек, Инк. Lc-ms/ms способ мониторинга множественных реакций для выявления терапевтических антител в образцах животных с помощью каркасных сигнатурных пептидов
AU2012264809B2 (en) 2011-05-27 2017-05-04 Ablynx Nv Inhibition of bone resorption with RANKL binding peptides
AU2012273928A1 (en) 2011-06-23 2014-02-06 Ablynx Nv Immunoglobulin single variable domains directed against IgE
BR112013030472A2 (pt) 2011-06-30 2019-09-24 Genentech Inc formulação farmacêutica, artigo de fabricação e método
WO2013004607A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
AU2012283235A1 (en) 2011-07-08 2014-01-09 Bayer Intellectual Property Gmbh Fusion proteins releasing Relaxin and uses thereof
US20130022551A1 (en) 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
JP5994068B2 (ja) * 2011-08-24 2016-09-21 国立大学法人 鹿児島大学 ＩｇＧ結合性ペプチド及びそれによるＩｇＧの検出および精製方法
EP2758422A1 (en) 2011-09-23 2014-07-30 Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA Modified albumin-binding domains and uses thereof to improve pharmacokinetics
DK2747782T3 (da) 2011-09-23 2018-04-23 Ablynx Nv Langvarig inhibering af interleukin-6-medieret signaloverførsel
SG10201504605RA (en) 2011-09-23 2015-07-30 Technophage Investigação E Desenvolvimento Em Biotecnologia Sa Anti-Tumor Necrosis Factor-Alpha Agents And Uses Thereof
CN106046161B (zh) 2011-09-30 2019-09-13 埃博灵克斯股份有限公司 与C-Met相关的生物物质
WO2013055987A1 (en) 2011-10-14 2013-04-18 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
PL2776466T3 (pl) 2011-11-11 2018-01-31 Ucb Biopharma Sprl Przeciwciała wiążące albuminę i ich fragmenty wiążące
WO2013128027A1 (en) * 2012-03-01 2013-09-06 Amgen Research (Munich) Gmbh Long life polypeptide binding molecules
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
US20160009767A9 (en) * 2012-03-28 2016-01-14 Affibody Ab Oral administration
JP2020033372A (ja) * 2012-03-28 2020-03-05 アフィボディ・アーベー 経口投与
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
KR102434075B1 (ko) 2012-05-17 2022-08-19 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
US8822423B2 (en) * 2012-05-17 2014-09-02 Janssen Biotech, Inc. Affinity peptides toward infliximab
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
JP2015519345A (ja) 2012-05-25 2015-07-09 ヤンセン バイオテツク，インコーポレーテツド 非天然コンセンサスアルブミン結合ドメイン
US9856314B2 (en) * 2012-06-22 2018-01-02 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and methods of using the same
WO2014003176A1 (ja) * 2012-06-29 2014-01-03 旭化成メディカル株式会社 プロテインａのｂドメイン変異体を含むポリペプチドが結合された担体からなる吸着材
US10155792B2 (en) 2012-09-25 2018-12-18 Affibody Ab Albumin binding polypeptide
WO2014057120A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
SI2906248T1 (sl) 2012-10-12 2019-02-28 Medimmune Limited Pirolobenzodiazepini in njihovi konjugati
RS57104B1 (sr) 2012-10-12 2018-06-29 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-antitela
PL2839860T3 (pl) 2012-10-12 2019-10-31 Medimmune Ltd Pirolobenzodiazepiny i ich koniugaty
EP2906250B1 (en) 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-psma antibody conjugates
MX364327B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina - anti-cd22.
CA2887895C (en) 2012-10-12 2019-10-29 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd19 antibody conjugates
AU2013328619B2 (en) 2012-10-12 2016-11-17 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-PSMA antibody conjugates
US9745340B2 (en) 2012-10-25 2017-08-29 Affibody Ab Method for the separation of proteins containing an albumin-binding
EP2912054B1 (en) 2012-10-25 2017-06-21 Affibody AB Albumin binding polypeptide
CN110627797A (zh) 2012-12-21 2019-12-31 麦迪穆有限责任公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP2752426A1 (en) 2013-01-03 2014-07-09 Covagen AG Human serum albumin binding compounds and fusion proteins thereof
EP2949750B1 (en) 2013-01-28 2019-11-13 National Institute of Advanced Industrial Science and Technology Antibody-binding peptide
US9821074B2 (en) 2013-03-13 2017-11-21 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
CN105142674B (zh) 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
EP2968587A2 (en) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
LT2970449T (lt) 2013-03-15 2019-11-25 Amgen Res Munich Gmbh Viengrandės surišančios molekulės, apimančios n galo abp
CN105636612B (zh) 2013-08-12 2020-01-14 基因泰克公司 抗体-药物缀合物及使用和治疗方法
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
BR112016013258A2 (pt) 2013-12-16 2018-01-16 Genentech Inc composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
PE20161394A1 (es) 2013-12-16 2017-01-06 Genentech Inc Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco
MX371092B (es) 2013-12-16 2020-01-16 Genentech Inc Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos.
EP3083675B1 (en) 2013-12-20 2018-03-07 Affibody AB Engineered albumin binding polypeptide
WO2015132248A2 (en) * 2014-03-03 2015-09-11 Vrije Universiteit Brussel (Vub) Sequamers - a novel non-natural type of peptide libraries randomly constrained by their primary sequences
SG11201607519VA (en) 2014-03-14 2016-10-28 Genentech Inc Methods and compositions for secretion of heterologous polypeptides
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety
CN106661125B (zh) 2014-05-02 2021-10-01 动量制药公司 涉及工程化Fc构建体的组合物和方法
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
BR112017003236A2 (pt) 2014-09-12 2017-11-28 Genentech Inc anticorpos elaborados com cisteína, conjugados de droga e anticorpos, método de preparação de conjugado de droga e anticorpo e composição farmacêutica
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
BR112017005393A2 (pt) 2014-09-17 2017-12-05 Genentech Inc composto de fórmula i, método de preparação de um conjugado de fórmula a, conjugado de fórmula a1, composição compreendendo uma mistura dos compostos de conjugado de anticorpo-fármaco, composição farmacêutica, e uso de um conjugado ou de uma composição
HUE049175T2 (hu) 2014-09-23 2020-09-28 Hoffmann La Roche Eljárás anti-CD79b immunkonjugátumok alkalmazására
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
EP3215533A2 (en) 2014-11-05 2017-09-13 F. Hoffmann-La Roche AG Anti-fgfr2/3 antibodies and methods using same
KR20170101895A (ko) 2014-11-25 2017-09-06 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 접합체
WO2016090050A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
CA2971414A1 (en) 2014-12-19 2016-06-23 Alexion Pharmaceuticals, Inc. Methods of treating tissue calcification
AU2016239844B2 (en) 2015-04-02 2021-05-13 Ablynx N.V. Bispecific CXCR4-CD-4 polypeptides with potent anti-HIV activity
EP3280432B8 (en) 2015-04-06 2021-04-14 Subdomain, LLC De novo binding domain containing polypeptides and uses thereof
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
WO2016180982A1 (en) 2015-05-13 2016-11-17 Ablynx N.V. T cell recruiting polypeptides based on cd3 reactivity
HUE045437T2 (hu) 2015-05-13 2019-12-30 Ablynx Nv TCR-alfa-béta reaktivitásán alapulva T-sejtet toborzó polipeptidek
CN107743494B (zh) 2015-06-02 2022-04-29 诺和诺德股份有限公司 具有极性重组延伸体的胰岛素
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
CN108137651B (zh) * 2015-10-23 2022-02-22 富士胶片株式会社 环肽、亲和层析载体、标记抗体、抗体药物复合物及药物制剂
MA43302A (fr) 2015-11-27 2021-03-17 Ablynx Nv Polypeptides inhibant le ligand cd40l
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
JP2019503394A (ja) 2016-01-31 2019-02-07 ユニバーシティ・オブ・マサチューセッツＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ 分岐オリゴヌクレオチド
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP7091248B2 (ja) 2016-03-01 2022-06-27 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ 低減されたｌ－グルタミナーゼ活性および増強された安定性を有するｌ－アスパラギナーゼ変異体および融合タンパク質
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
IL262367B (en) 2016-04-15 2022-09-01 Berkeley Lights Inc Systems methods and kits for tests based on isolation in a confinement cell
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
PL3484514T3 (pl) 2016-05-23 2024-04-29 Momenta Pharmaceuticals, Inc. Kompozycje i sposoby związane z projektowanymi konstruktami Fc
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
KR102461666B1 (ko) 2016-06-03 2022-11-01 얀센 바이오테크 인코포레이티드 혈청 알부민 결합 피브로넥틴 iii 형 도메인
EP3471747A1 (en) 2016-06-16 2019-04-24 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
CA3033368A1 (en) 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
WO2018043629A1 (ja) 2016-09-01 2018-03-08 国立研究開発法人産業技術総合研究所 非天然型立体構造を形成した抗体に親和性を示すポリペプチド
EP3512880A1 (en) 2016-09-15 2019-07-24 Ablynx NV Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
SG11201902818PA (en) * 2016-09-30 2019-05-30 Fujifilm Corp Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
CA3043179A1 (en) * 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Gdnf fusion polypeptides and methods of use thereof
CN117700549A (zh) 2016-11-16 2024-03-15 埃博灵克斯股份有限公司 能够结合CD123和TCRα/β的T细胞募集多肽
AU2018205808A1 (en) 2017-01-06 2019-07-25 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered Fc constructs
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
WO2018146189A1 (en) 2017-02-08 2018-08-16 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2018185131A2 (en) 2017-04-05 2018-10-11 Novo Nordisk A/S Oligomer extended insulin-fc conjugates
RS63502B1 (sr) 2017-04-18 2022-09-30 Medimmune Ltd Konjugati pirolobenzodiazepina
EP3612234B1 (en) 2017-04-20 2024-03-13 ADC Therapeutics SA Combination therapy with an anti-axl antibody-drug conjugate
WO2018199337A1 (ja) 2017-04-28 2018-11-01 味の素株式会社 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
AR112069A1 (es) 2017-06-02 2019-09-18 Ablynx Nv Inmunoglobulinas que fijan aggrecan
CA3064469A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Mmp13 binding immunoglobulins
WO2018220234A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Adamts binding immunoglobulins
BR112019025147A2 (pt) 2017-06-02 2020-06-23 Merck Patent Gmbh Polipeptídeos que ligam adamts5, mmp13 e aggrecan
JP7145891B2 (ja) 2017-06-14 2022-10-03 アーデーセー セラピューティクス ソシエテ アノニム 抗ｃｄ１９ ａｄｃを投与するための投与レジメ
CA3064590A1 (en) 2017-06-23 2018-12-27 University Of Massachusetts Two-tailed self-delivering sirna and related methods
CN117327187A (zh) 2017-07-11 2024-01-02 亚力兄制药公司 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
CN111164104A (zh) * 2017-08-09 2020-05-15 麻省理工学院 白蛋白结合肽缀合物及其方法
ES2965372T3 (es) 2017-08-11 2024-04-15 Univ Illinois Variantes de L-asparaginasa de cobaya truncada y métodos de uso
HRP20220311T1 (hr) 2017-08-18 2022-05-13 Medimmune Limited Konjugati pirolobenzodiazepina
CA3096821A1 (en) 2017-09-27 2019-04-04 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
MX2020003562A (es) 2017-10-10 2020-10-01 Numab Therapeutics AG Anticuerpo multiespecifico.
WO2019075476A2 (en) 2017-10-15 2019-04-18 Berkeley Lights, Inc. METHODS, SYSTEMS AND KITS FOR ENCLOSED TESTS
JP7356435B2 (ja) 2017-11-14 2023-10-04 アーセルクス インコーポレイテッド 多機能性免疫細胞療法
KR102037336B1 (ko) * 2017-11-29 2019-10-29 아주대학교산학협력단 항체와 생리활성물질의 접합방법
WO2019107962A2 (ko) * 2017-11-29 2019-06-06 아주대학교 산학협력단 항체와 생리활성물질의 접합방법
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2019240288A1 (ja) 2018-06-14 2019-12-19 味の素株式会社 抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩
CN113166266A (zh) 2018-06-18 2021-07-23 安维塔生物科学股份有限公司 抗间皮素构建体及其用途
WO2020033899A1 (en) 2018-08-10 2020-02-13 University Of Massachusetts Modified oligonucleotides targeting snps
KR20210087027A (ko) 2018-09-27 2021-07-09 실리오 디벨럽먼트, 인크. 마스킹된 사이토카인 폴리펩타이드
CN113227124A (zh) 2018-10-31 2021-08-06 味之素株式会社 具有针对抗体的亲和性物质、切割性部分及反应性基团的化合物或其盐
JP2022513198A (ja) 2018-12-10 2022-02-07 ジェネンテック， インコーポレイテッド Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
SG11202105215QA (en) * 2018-12-20 2021-06-29 Kleo Pharmaceuticals Inc Combination therapy of arms and natural killer cells
WO2020150636A1 (en) * 2019-01-18 2020-07-23 University Of Massachusetts Dynamic pharmacokinetic-modifying anchors
US12024706B2 (en) 2019-08-09 2024-07-02 University Of Massachusetts Modified oligonucleotides targeting SNPs
EP3816185A1 (en) 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
EP3915580A1 (en) 2020-05-29 2021-12-01 Numab Therapeutics AG Multispecific antibody
KR20230030587A (ko) 2020-06-30 2023-03-06 가부시키가이샤 가이아바이오메디신 Nk 세포와 항체의 결합을 안정화시키는 방법, 및 그 이용
EP3988568A1 (en) 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
CN116670166A (zh) 2020-12-07 2023-08-29 Ucb生物制药有限责任公司 多特异性抗体和抗体组合
MX2023009022A (es) 2021-02-02 2023-10-23 Numab Therapeutics AG Anticuerpos multiespecificos con especificidad para ror1 y cd3.
EP4294834A2 (en) 2021-02-19 2023-12-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Single domain antibodies that neutralize sars-cov-2
BR112023026862A2 (pt) 2021-06-23 2024-03-05 Beth Israel Deaconess Medical Ct Inc Compostos de oligonucleotídeos anti-flt1 otimizados para tratamento de pré-eclâmpsia e outros distúrbios angiogênicos
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
WO2023167564A1 (ko) 2022-03-04 2023-09-07 앱티스 주식회사 티올 반응성 에디티브를 이용한 항체-약물 컨쥬게이트의 제조 수율을 높이는 방법
WO2024008904A2 (en) 2022-07-08 2024-01-11 Novo Nordisk A/S Highly potent isvd compounds capable of substituting for fviii(a)
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US763829A (en) 1903-01-16 1904-06-28 L E Knott Apparatus Company Apparatus for reading angular deflections.
US3561444A (en) * 1968-05-22 1971-02-09 Bio Logics Inc Ultrasonic drug nebulizer
US3703173A (en) 1970-12-31 1972-11-21 Ted A Dixon Nebulizer and tent assembly
US3862925A (en) * 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US3842067A (en) * 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
JPS5726506B2 (da) * 1974-03-08 1982-06-04
US4105603A (en) 1977-03-28 1978-08-08 The Salk Institute For Biological Studies Peptides which effect release of hormones
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4635627A (en) * 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
US4624251A (en) 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4824659A (en) * 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5079233A (en) * 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
IE81149B1 (en) 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5223427A (en) 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
US5606040A (en) * 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
JPH04501201A (ja) 1987-12-21 1992-03-05 ジ・アップジョン・カンパニー 発芽植物種子類のアグロバクテリウム媒介形質転換
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
EP0429537A4 (en) 1988-08-18 1991-08-21 California Biotechnology, Inc. Atrial natriuretic peptide clearance inhibitors
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
WO1992000748A1 (en) 1990-07-06 1992-01-23 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1992016555A1 (en) 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
AU665599B2 (en) * 1991-11-08 1996-01-11 Hemosol Inc. Hemoglobins as drug delivery agents
US5288931A (en) 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
EP0602290B1 (en) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
JP3469580B2 (ja) * 1993-10-01 2003-11-25 帝国臓器製薬株式会社 新規なペプチド誘導体
US5627263A (en) 1993-11-24 1997-05-06 La Jolla Cancer Research Foundation Integrin-binding peptides
SE9400088D0 (sv) * 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
EP0833911B1 (en) 1995-06-07 2004-05-12 Ortho Pharmaceutical Corporation Cdr-grafted anti-tissue factor antibodies and methods of use thereof
US5780054A (en) * 1996-01-17 1998-07-14 University Of British Columbia Methods for increasing the circulation half-life of protein-based therapeutics
AU7298398A (en) * 1996-11-19 1998-06-10 Sangstat Medical Corporation Enhanced effects for hapten conjugated therapeutics
EP1787999B1 (en) 1997-04-07 2010-08-04 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DK1240337T3 (da) 1999-12-24 2007-01-02 Genentech Inc Fremgangsmåder og præparater til forlængelse af elimeneringshalveringstider af bioaktive forbindelser
US20060228364A1 (en) * 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US6632979B2 (en) * 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
AU2002335930B2 (en) * 2001-03-09 2005-07-28 Morphosys Ag Serum albumin binding moieties
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20030009395A1 (en) * 2001-07-06 2003-01-09 Yu Philip Shi-Lung Method and apparatus for providing information regarding a product
SG177002A1 (en) 2001-10-10 2012-01-30 Novo Nordisk As Remodeling and glycoconjugation of peptides
CA2467242A1 (en) 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
ES2401428T3 (es) * 2002-04-10 2013-04-19 Genentech, Inc. Variantes de anticuerpos anti-HER2
JP3997859B2 (ja) * 2002-07-25 2007-10-24 株式会社日立製作所 半導体装置の製造方法および製造装置
CA2494104A1 (en) 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
US20040032828A1 (en) * 2002-08-16 2004-02-19 Cellglide Technologies Corp. Service management in cellular networks

Also Published As

Publication number Publication date
JP4949132B2 (ja) 2012-06-06
AU2009201933A1 (en) 2009-06-04
CA2390691C (en) 2016-05-10
CA2921260A1 (en) 2001-06-28
US7608681B2 (en) 2009-10-27
AU2006202341A1 (en) 2006-06-29
AU2006202341B2 (en) 2009-02-19
ATE422369T1 (de) 2009-02-15
EP2180054A1 (en) 2010-04-28
DE60041564D1 (de) 2009-03-26
DE60030323T2 (de) 2007-10-11
WO2001045746A3 (en) 2001-10-11
EP1240337A2 (en) 2002-09-18
WO2001045746A2 (en) 2001-06-28
PT1240337E (pt) 2007-01-31
AU2009201933B2 (en) 2013-01-10
CY1106236T1 (el) 2011-06-08
JP5004640B2 (ja) 2012-08-22
US20070160534A1 (en) 2007-07-12
JP2007289200A (ja) 2007-11-08
CA2390691A1 (en) 2001-06-28
JP2003518075A (ja) 2003-06-03
ES2270893T3 (es) 2007-04-16
US20100121039A1 (en) 2010-05-13
ATE337403T1 (de) 2006-09-15
JP2007289187A (ja) 2007-11-08
DE60030323D1 (de) 2006-10-05
AU2458701A (en) 2001-07-03
US7635749B2 (en) 2009-12-22
EP1240337B1 (en) 2006-08-23
AU784285B2 (en) 2006-03-02
US20040253247A1 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
DK1240337T3 (da) Fremgangsmåder og præparater til forlængelse af elimeneringshalveringstider af bioaktive forbindelser
ATE425181T1 (de) Therapeutische zusammensetzungen aus antikorper und antisens nukleinsäuren gegen serrate
ATE277081T1 (de) Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
ES2141128T3 (es) Combinacion de agentes anti-hormonales y moleculas de fijacion.
ATE444361T1 (de) Il-17 und il-17r homologe polypeptide und deren therapeutische verwendungen
ES2058614T3 (es) 1,2-ciclohexilaminoarilaminadas utiles como agentes analgesicos.
WO2005003296A3 (en) Albumin fusion proteins
ATE549347T1 (de) Gene von säugetiere, und damit verbundene reagentien, methoden
ATE443074T1 (de) Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren
WO2001079444A3 (en) Albumin fusion proteins
WO2003060071A3 (en) Albumin fusion proteins
AU8700291A (en) Hcv-specific peptides, agents therefor and the use thereof
WO2003030821A3 (en) Albumin fusion proteins
DE69434384D1 (de) Metalkomplexbildner
MXPA02008239A (es) Gen humano de la esquizofrenia.
ATE333469T1 (de) Verfahren zur reinigung hochanionischer proteine
BR0312889A (pt) Polipeptìdeo t20 peguilado
ATE385517T1 (de) Interferon ähnliche moleküle, und deren verwendungen
ATE196775T1 (de) Gereinigte flt3 liganden von saeugentieren, agonisten und antagonisten davon
EA200300246A1 (ru) Ген и белок, ассоциированные с шизофренией
ATE432349T1 (de) Modifizierte hämoglobinähnliche verbindungen und verfahren zu deren reinigung
WO2001071007A3 (en) GENETIC POLYMORPHISM OF MxA PROTEIN AND USE THEREOF
EP1757311A3 (en) Methods and compositions for prolonging elimination half-times of bioactive compounds
ATE397662T1 (de) Neues polypeptid, dafür kodierende dna und deren verwendungen
WO2001064876A3 (en) Human schizophrenia gene